{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:41Z","timestamp":1792685981687,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["00P3_157476"],"award-info":[{"award-number":["00P3_157476"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.msard.2022.103887","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T01:26:17Z","timestamp":1652577977000},"page":"103887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3186-1562","authenticated-orcid":false,"given":"S.","family":"Borrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Le","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Du","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Th\u00e9audin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103887_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103740","article-title":"Lymphopenia in multiple sclerosis patients treated with ocrelizumab is associated with an effect on CD8 T cells","volume":"60","author":"Abbadessa","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2022.103887_bib0036","article-title":"A retrospective analysis of changes in lymphocyte levels in patients with multiple sclerosis during and after Tecfidera(R) treatment","volume":"7","author":"Baeva","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2022.103887_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419843450","article-title":"Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age","volume":"12","author":"Briner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.msard.2022.103887_bib0026","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1212\/CPJ.0000000000000800","article-title":"Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS","volume":"10","author":"Chan","year":"2020","journal-title":"Neurol. Clin. Pract."},{"issue":"2","key":"10.1016\/j.msard.2022.103887_bib0030","article-title":"Lymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate","volume":"3","author":"Chaves","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"9","key":"10.1016\/j.msard.2022.103887_bib0038","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1177\/1352458519851981","article-title":"Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: pooled analysis of clinical trials","volume":"26","author":"Comi","year":"2020","journal-title":"Mult. Scler."},{"issue":"Pt 9","key":"10.1016\/j.msard.2022.103887_bib0045","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","article-title":"A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy","volume":"127","author":"Du Pasquier","year":"2004","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.msard.2022.103887_bib0001","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103887_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102781","article-title":"Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment","volume":"49","author":"Garbo","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2022.103887_bib0028","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1212\/NXI.0000000000000340","article-title":"Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis","volume":"4","author":"Ghadiri","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2022.103887_bib0034","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00415-017-8509-9","article-title":"Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases","volume":"264","author":"Gieselbach","year":"2017","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.103887_bib0002","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.msard.2022.103887_bib0012","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1177\/1352458517690617","article-title":"Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies","volume":"23","author":"Gopal","year":"2017","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2022.103887_bib0010","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/acn3.553","article-title":"The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis","volume":"5","author":"Hammer","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103887_bib0007","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/ene.13272","article-title":"Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies","volume":"24","author":"Havrdova","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.103887_bib0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.msard.2016.08.002","article-title":"Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up","volume":"10","author":"Hersh","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2022.103887_bib0005","article-title":"Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up","volume":"3","author":"Hersh","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2022.103887_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103003","article-title":"Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate","volume":"52","author":"Lee","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2022.103887_bib0017","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1093\/brain\/awab307","article-title":"Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity","volume":"144","author":"Liebmann","year":"2021","journal-title":"Brain"},{"issue":"Pt 3","key":"10.1016\/j.msard.2022.103887_bib0009","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2022.103887_bib0019","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1177\/1352458514559299","article-title":"Dimethyl fumarate associated lymphopenia in clinical practice","volume":"21","author":"Longbrake","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103887_bib0018","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"8","key":"10.1016\/j.msard.2022.103887_bib0031","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1177\/1352458515608961","article-title":"Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients","volume":"22","author":"Longbrake","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103887_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.679355","article-title":"The dimethyl fumarate experience: a handy drug with broad clinical utility","volume":"12","author":"Lorefice","year":"2021","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.103887_bib0035","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2022.103887_bib0021","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00415-021-10412-0","article-title":"Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis","volume":"268","author":"Lucchini","year":"2021","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.103887_bib0011","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1212\/NXI.0000000000000099","article-title":"Glial cells express nuclear nrf2 after fumarate treatment for multiple sclerosis and psoriasis","volume":"2","author":"Metz","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.103887_bib0016","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fneur.2018.00005","article-title":"Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis","volume":"9","author":"Mills","year":"2018","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.103887_bib0042","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1038\/s41598-018-26519-w","article-title":"Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients","volume":"8","author":"Montes Diaz","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2022.103887_bib0022","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-019-09557-w","article-title":"Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Morales","year":"2020","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2022.103887_bib0037","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2165\/00002018-200427100-00005","article-title":"Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis","volume":"27","author":"Rieckmann","year":"2004","journal-title":"Drug Saf."},{"issue":"15","key":"10.1016\/j.msard.2022.103887_bib0032","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJMc1415408","article-title":"PML in a patient with lymphocytopenia treated with dimethyl fumarate","volume":"372","author":"Rosenkranz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103887_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2019.01.007","article-title":"Factors associated with dimethyl fumarate-induced lymphopenia","volume":"398","author":"Sainz de la Maza","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2022.103887_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103669","article-title":"Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis","volume":"59","author":"Sainz de la Maza","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103887_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211021177","article-title":"A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod","volume":"14","author":"Salter","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2022.103887_bib0008","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1124\/jpet.111.190132","article-title":"Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway","volume":"341","author":"Scannevin","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"17","key":"10.1016\/j.msard.2022.103887_bib0014","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1073\/pnas.1603907113","article-title":"Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2","volume":"113","author":"Schulze-Topphoff","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.msard.2022.103887_bib0027","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1212\/NXI.0000000000000076","article-title":"Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate","volume":"2","author":"Spencer","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.103887_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730342","article-title":"Teriflunomide treatment of multiple sclerosis selectively modulates CD8 memory T cells","volume":"12","author":"Tilly","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2022.103887_bib0043","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1523-1747.2003.12605.x","article-title":"Dimethylfumarate is a potent inducer of apoptosis in human T cells","volume":"121","author":"Treumer","year":"2003","journal-title":"J. Invest. Dermatol."},{"issue":"8","key":"10.1016\/j.msard.2022.103887_bib0044","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.biopha.2014.09.009","article-title":"Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-kappaB nuclear translocation and down-regulation of Bcl-xL and XIAP","volume":"68","author":"Tsubaki","year":"2014","journal-title":"Biomed. Pharmacother."},{"issue":"17","key":"10.1016\/j.msard.2022.103887_bib0033","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","article-title":"PML in a patient treated with dimethyl fumarate from a compounding pharmacy","volume":"368","author":"van Oosten","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103887_bib0013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.msard.2018.02.027","article-title":"The putative interplay between DJ-1\/NRF2 and Dimethyl Fumarate: a potentially important pharmacological target","volume":"21","author":"Vavougios","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2022.103887_bib0015","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1212\/NXI.0000000000000397","article-title":"Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation","volume":"4","author":"Wright","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2022.103887_bib0029","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.4049\/jimmunol.1601532","article-title":"Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1\/Th17 and Th2 in multiple sclerosis patients","volume":"198","author":"Wu","year":"2017","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2022.103887_bib0039","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ane.12882","article-title":"Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation","volume":"137","author":"Zecca","year":"2018","journal-title":"Acta Neurol. Scand."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:16Z","timestamp":1761901456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822003996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":46,"alternative-id":["S2211034822003996"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103887","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103887"}}